Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...